Nkarta, Inc.

NASDAQ:NKTX

Biotechnology

Healthcare
$1.15 +3.41%

+$0.09 today

Market cap
$82.37M
Beta
0.90
P/E (TTM)
-2.0
EPS (TTM)
-$1.35
52W Low $1.63High $3.65

Volume 0.81M

Average 0.75M

NKTX Total Non-current Liabilities

All obligations due after more than one year.

Nkarta, Inc.NASDAQ: NKTX

Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026

Total non-current liabilities falls 6.9% from a year ago

Total non-current liabilities stood at $68.01M at the end of Q1 FY2026, down 6.9% from a year earlier and down 2.3% from the prior quarter. Over 3 fiscal years it compounded at -4.0% a year.

Context

  • Total non-current liabilities amounted to 18.3% of total assets at the end of Q1 FY2026, up 2.8 pp from a year earlier.
  • Total non-current liabilities increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -6.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$68.01M-2.3% QoQ
Last fiscal yearDec 2025
$69.62M-6.3% YoY
Year agoMar 2025
$73.05M-6.9% since
Total Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-6.9%——
1 year-6.3%——
3-year CAGR-4.0%——
5-year CAGR——
10-year CAGR——

Total Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
69.62M USD
Year-over-year change
-6.3%
4-year CAGR
+62.5%

Total Non-current Liabilities vs competitors

How NKTX compares with its peers on the latest reported figures

  • Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -6.9% is the 4th highest of 7, against a peer median of +54.2%.
  • Total non-current liabilities amounts to 18.3% of total assets for NKTX, versus a peer median of 26.2%.
NKTX Competitors
Total Non-current Liabilities for NKTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
VORVor Biopharma Inc.Mar 2026$641.09M USD+2317.8%+156.8%126.5%
ALECAlector, Inc.Mar 2026$188.57M USD-7.5%-26.1%78.6%
FATEFate Therapeutics, Inc.Mar 2026$74.52M USD-9.2%-11.1%26.2%
NKTXNkarta, Inc.Mar 2026$68.01M USD-6.9%-4.0%18.3%
ELTXElicio Therapeutics, Inc.Mar 2026$16.9M USD+115.9%+32.8%74.5%
PEPGPepGen Inc.Mar 2026$13.35M USD-11.9%-10.0%8.5%
MOLNMolecular Partners AGMar 2026CHF 10.38M CHF+163.4%+3.0%11.9%
FBRXForte Biosciences, Inc.Mar 2026$1.48M USD——2.2%
Peer median (excluding NKTX) —+54.2%-3.5%26.2%

Competitors are the stored peer set for NKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents60.82M37.49M31.04M27.87M39.63M
Short-term Investments177.27M314.65M217.15M239.48M236.65M
Net Receivables01.3M200K200K2M
Inventory00000
Other Current Assets3.15M1.63M1.42M2.54M414K
Total Current Assets245.78M360.69M253.07M273.34M282.51M
Property, Plant & Equipment (Net)24.53M107.66M119.28M110.67M101.15M
Goodwill00000
Intangible Assets00000
Long-term Investments02.74M2.74M110.39M16.11M
Tax Assets00000
Other Non-current Assets3.59M1.85M3.8M6.8M4.44M
Total Non-current Assets28.12M112.25M125.81M227.87M121.7M
Total Assets273.9M472.94M378.89M501.2M404.21M
Account Payables1.11M1.76M3.67M638K2.09M
Short-term Debt04.25M000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities96K9.35M6.72M254K6.07M
Total Current Liabilities12.94M22.05M23.33M18.92M22.27M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities18K0087K87K
Total Non-current Liabilities9.99M78.69M82.27M74.31M69.62M
Total Liabilities22.94M100.73M105.6M93.23M91.88M
Common Stock3K5K5K7K7K
Retained Earnings(204.1M)(317.93M)(435.43M)(544.22M)(648.31M)
Accumulated OCI(150K)(679K)8K674K407K
Other Stockholders Equity(0)0000
Minority Interest00000
Total Equity250.97M372.21M273.29M407.98M312.33M
Total Debt12.46M82.93M88.34M80.27M76.42M
Net Debt(48.36M)45.44M57.3M52.4M36.79M

Nkarta, Inc.

NASDAQ:NKTX

Intrinsic Alpha fair value

Locked

Current Price

$1.15

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.